Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - Time to Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw strong trading volume on Wednesday . 520,306 shares were traded during mid-day trading, an increase of 113% from the previous session's volume of 244,454 shares.The stock last traded at $17.54 and had previously closed at $16.83.

Analyst Ratings Changes

A number of equities research analysts have issued reports on DNTH shares. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Guggenheim reiterated a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating for the company. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average target price of $54.33.

Dianthus Therapeutics Trading Down 5.7 %

The firm has a market cap of $488.33 million, a P/E ratio of -6.08 and a beta of 1.62. The stock has a 50 day simple moving average of $21.48 and a 200-day simple moving average of $23.89.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in DNTH. FMR LLC raised its holdings in shares of Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company's stock worth $96,776,000 after buying an additional 36,133 shares during the period. Octagon Capital Advisors LP increased its holdings in Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after purchasing an additional 363,500 shares during the period. TCG Crossover Management LLC bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $32,735,000. Braidwell LP lifted its holdings in shares of Dianthus Therapeutics by 144.4% in the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after buying an additional 712,902 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in Dianthus Therapeutics by 13.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock worth $25,283,000 after acquiring an additional 136,633 shares during the period. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.